Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Current Deferred Revenue (2016 - 2024)

Lexaria Bioscience's Current Deferred Revenue history spans 6 years, with the latest figure at $4963.0 for Q3 2024.

  • For Q3 2024, Current Deferred Revenue changed N/A year-over-year to $4963.0; the TTM value through Aug 2024 reached $4963.0, changed N/A, while the annual FY2024 figure was $4963.0, N/A changed from the prior year.
  • Current Deferred Revenue for Q3 2024 was $4963.0 at Lexaria Bioscience, up from $4275.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $44255.0 in Q3 2020 and bottomed at $1000.0 in Q1 2021.
  • The 4-year median for Current Deferred Revenue is $5606.5 (2020), against an average of $16040.5.